Nomura analyst Christopher Marai maintained a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) on Friday, setting a price target of $230, which is approximately 55.42% above the present share price of $147.99.
Marai expects Sarepta Therapeutics to post earnings per share (EPS) of -$0.23 for the second quarter of 2020.
The current consensus among 16 TipRanks analysts is for a Strong Buy rating of shares in Sarepta Therapeutics, with an average price target of $196.31.
The analysts price targets range from a high of $260 to a low of $152.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $113.67 million and a net profit of -$118.03 million. The company's market cap is $11.54 billion.
According to TipRanks.com, Nomura analyst Christopher Marai is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 2.7% and a 48.76% success rate.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.